

PIASx β acts as an activator of *Hoxb1* and is antagonized by Krox20 during hindbrain segmentation

Mario Garcia-Dominguez^{1,2,3}
Pascale Gilardi-Hebenstreit^{1,3}
and Patrick Charnay^{1,*}

¹INSERM, U 784, Ecole Normale Supérieure, Paris, France and ²Instituto de Bioquímica Vegetal y Fotosíntesis, Isla de la Cartuja, Sevilla, Spain

The zinc-finger transcription factor Krox20 constitutes a key regulator of hindbrain development, essential for the formation and specification of rhombomeres (r) 3 and 5. It is in particular responsible for the respective activation and repression of odd- and even-numbered rhombomere-specific genes, which include *Hox* genes. In this study, we have identified PIASx β as a novel direct interactor of Krox20. In addition, we found that PIASx β is able to activate the r4-specific gene *Hoxb1*. Binding of Krox20 prevents this activation, providing a molecular basis for the repression of *Hoxb1* by Krox20. The same domain in the Krox20 protein, the zinc-fingers, is involved in DNA binding for transcriptional activation and in interaction with PIASx β for transcriptional repression, although the actual precise contacts are different. Our findings add an additional level in the complexity of *Hox* gene regulation and provide an example of how a single regulator can coordinate the activation and repression of a set of genes by very different mechanisms, acting as a molecular switch to specify cell identity and fate.

The EMBO Journal (2006) 25, 2432–2442. doi:10.1038/sj.emboj.7601122; Published online 4 May 2006

Subject Categories: chromatin & transcription; development
Keywords: hindbrain segmentation; *Hox* gene; pattern formation; transcription control

Introduction

The development of the vertebrate hindbrain involves a transient segmentation process along the anterior–posterior (AP) axis leading to the formation of 7–8 transversal morphological units, called rhombomeres (r) (reviewed in Lumsden and Krumlauf, 1996). The rhombomeres behave as compartments, constituting units of cell lineage restriction (Fraser *et al.*, 1990) and domains of specific gene expression (reviewed in Lumsden and Krumlauf, 1996). This subdivision presages the metamer pattern of neuronal specification in the hindbrain (Clarke *et al.*, 1998), underlies the pathways of

neural crest cell migration into the branchial arches and participates in its patterning (Birgbauer *et al.*, 1995; Trainor and Krumlauf, 2000), thus playing an essential role in craniofacial morphogenesis.

Numerous genes have been implicated at different levels of the segmentation process, including the initial formation of segmental territories (Frohman *et al.*, 1993; Schneider-Maunoury *et al.*, 1993; Barrow *et al.*, 2000; Choe and Sagerstrom, 2004; McNulty *et al.*, 2005 and references therein), the specification of their AP identities (Rijli *et al.*, 1993; Studer *et al.*, 1996; Seitanidou *et al.*, 1997; Rossel and Capecchi, 1999), the stabilization of the pattern by restriction of cell intermingling between adjacent rhombomeres (reviewed in Pasini and Wilkinson, 2002) and the development of specific cell populations at boundaries (Cheng *et al.*, 2004). Segment formation and specification are highly intricate processes in the hindbrain (Gavalas *et al.*, 1998; Rossel and Capecchi, 1999; Voiculescu *et al.*, 2001), relying on a complex network of transcription factors. *Hox* proteins play a key role in this network, which receives inputs from several signalling cascades, including the FGF and retinoid pathways, acting both intrinsically and extrinsically to the neuroepithelium (Marin and Charnay, 2000; Dupe and Lumsden, 2001; Walshe *et al.*, 2002; Serpente *et al.*, 2005). Deciphering *Hox* gene regulation and function therefore appears as an essential step in our understanding of the molecular mechanisms controlling hindbrain segmentation.

A key regulator of *Hox* genes in the hindbrain is *Krox20*, which encodes a zinc-finger transcription factor expressed in r3 and r5 and is essential for the development and specification of these segments (Schneider-Maunoury *et al.*, 1993; Seitanidou *et al.*, 1997; Voiculescu *et al.*, 2001). *Krox20* has been shown to directly activate the transcription of several *Hox* genes (*Hoxb2*, *Hoxa2* and *Hoxb3*) by binding to nearby transcriptional enhancers (Sham *et al.*, 1993; Nonchev *et al.*, 1996; Manzanares *et al.*, 2002). *Krox20* was also shown to repress the expression of another *Hox* gene, *Hoxb1*, although the mechanisms underlying this second type of transcriptional regulation mediated by *Krox20* have not been elucidated (Seitanidou *et al.*, 1997; Giudicelli *et al.*, 2001; Voiculescu *et al.*, 2001). A likely possibility is that *Krox20* exerts positive and negative activities on transcription by interacting with different cofactors. Several *Krox20* interactors have been identified, including NAB1 and NAB2, which modulate its transcriptional activity (Russo *et al.*, 1995; Svaren *et al.*, 1996). So far, however, these factors cannot account for the dual transcriptional activity of *Krox20* in the hindbrain.

In the present work, we have performed a two-hybrid screening designed to identify novel *Krox20* interactors that might be involved in the different aspects of *Hox* gene regulation by *Krox20*. Among the positive clones, we have identified PIASx β . PIAS (protein inactivator of activated

*Corresponding author. INSERM, U 784, Ecole Normale Supérieure, 46, rue d'Ulm, 75230 Paris Cedex 05, France. Tel.: +33 1 4432 3607;

Fax: +33 1 4432 3988; E-mail: charnay@wotan.ens.fr

³These authors contributed equally to this work

Received: 28 September 2005; accepted: 6 April 2006; published online: 4 May 2006

STAT) proteins were first reported as inhibitors of the DNA-binding and transcription activation by STAT (signal transducer and activator of transcription) (Shuai, 2000). The PIAS mammalian family includes at least five members: PIAS1, PIAS3, PIASx (with two isoforms, PIASxα or ARIP3, and PIASxβ or Miz1) and PIASγ (Shuai, 2000; Johnson, 2004). In addition to their role in the modulation of transcription, they have been shown to carry an E3 ligase activity for the small ubiquitin-related modifier proteins (SUMO) (Johnson, 2004). We have found that PIASxβ is expressed in the developing neural tube, that its overexpression leads to ectopic *Hoxb1* activation and that a specific PIASxβ deletion mutant represses *Hoxb1* expression, presumably acting as a dominant-negative molecule. Our findings identify PIASxβ as a novel positive regulator of *Hoxb1* in the hindbrain. We also show that Krox20 antagonizes this novel activity of PIASxβ and that its ability to repress *Hoxb1* does not require its DNA-binding activity, but its capacity to interact with PIASxβ. Together, these data reveal a novel mechanism of control of *Hox* gene expression by Krox20, in which repression is mediated by antagonizing a positive regulatory factor.

Results

Krox20 interacts with PIASxβ

In an attempt to identify factor(s) interacting with Krox20 during hindbrain development, we performed a yeast two-hybrid screening. As full-length Krox20 fused to the Gal4 DNA-binding domain was able alone to activate the transcrip-

tion of a β-galactosidase reporter linked to Gal4 binding sites (data not shown), we decided to use as bait a Krox20 deletion (Krox20(184–470)), lacking the N-terminal part containing the known transcriptional activation domains (Figure 1A; Vesque and Charnay, 1992). Yeast cells containing the expression plasmid for the fusion protein between Krox20(184–470) and the Gal4 DNA-binding domain were transfected with a library of 8.5 dpc mouse embryo cDNAs fused to the Gal4 activation domain coding sequence. Approximately 2.5×10^6 transformants were screened on the basis of transcriptional activation of survival factors through Gal4 binding sites (see Materials and methods). Selected clones were further checked for their level of expression of the β-galactosidase reporter mentioned above. A total of 26 clones were finally retained at this stage and nucleotide sequence analysis of the cDNAs revealed that they corresponded to 12 different genes. Two of them corresponded to already known Krox20 cofactors, Nab1 and Nab2 (Russo *et al*, 1995; Svaren *et al*, 1996) (two and six clones, respectively), indicating that the two-hybrid selection was performed appropriately. The 10 newly identified putative Krox20 partners included PIASxβ (represented by a single clone), which we selected for further analysis on the basis of preliminary investigations (data not shown).

Comparison of the selected PIASxβ clone with available mouse ESTs revealed that it lacked the sequence encoding the three N-terminal amino acids and the cDNA was therefore completed. In a first series of experiments, we attempted to confirm the Krox20–PIASxβ interaction by GST pull-down




Figure 1 Krox20 interacts with PIASxβ. (A) Schematic structure of the Krox20 protein showing the location of the transactivation domains, NAB interaction domain (R1) and DNA-binding domain (zinc-fingers). Numbers below the line indicate amino-acid positions. The 287 C-terminal amino acids were used as bait in the two-hybrid screening. (B) *In vitro* binding of Krox20 and PIASxβ. *In vitro*-translated, ^{35}S -labelled luciferase and PIASxβ were resolved by SDS-PAGE and detected by fluorography. Left: 10% of the input was directly deposited on gel; right: luciferase or PIASxβ retained on GST or GST-Krox20 beads was analysed. PIASxβ specifically binds to GST-Krox20. (C) Colocalization of Krox20 and PIASxβ in the cell nucleus. COS7 cells were transfected with expression vectors encoding Krox20 and/or HA-PIASxβ and 36 h later the proteins were revealed by immunofluorescence analysis (Krox20 is labelled with FITC (green) and HA-PIASxβ with Cy3 (red)). When transfected alone, Krox20 appeared homogeneously distributed within the nucleus, whereas PIASxβ localized to nuclear bodies. Cotransfection led to a re-distribution of Krox20, with colocalization of both proteins. (D) Co-immunoprecipitation of Krox20 and PIASxβ. COS7 cells were cotransfected with expression vectors encoding Krox20 and HA-PIASxβ. Cell lysates were subjected to immunoprecipitation with antibodies directed against Krox20 or Flag, or with no antibody (control) and the precipitates were subsequently analysed by Western blotting using an anti-HA antibody.

experiments. For this purpose, we prepared GST and GST-Krox20 fusion proteins that were incubated with radio-labelled, *in vitro*-translated PIASx β or luciferase as a control. As shown in Figure 1B, GST-Krox20, but not GST alone, specifically retained PIASx β . These data establish that Krox20 and PIASx β can interact *in vitro* and that the interaction is direct.

To determine whether Krox20 and PIASx β also interact in mammalian cells, we transfected COS7 cells with expression vectors for Krox20 and an N-terminally HA-tagged version of PIASx β , alone or in combination. The cellular localization of the proteins was established by immunofluorescence performed with antibodies directed against Krox20 and the HA epitope (Figure 1C). When the expression vectors were transfected alone, Krox20 appeared distributed relatively homogeneously within the nucleus, whereas PIASx β presented a punctuated nuclear pattern, consistent with its previous localization to nuclear bodies (Kotaja *et al*, 2002). When both expression vectors were cotransfected, the nuclear distribution of Krox20 was modified towards a punctuated pattern, largely overlapping with that of PIASx β (Figure 1C). These data suggest that Krox20 and PIASx β colocalize when they are coexpressed, owing to sequestering of Krox20 by PIASx β in nuclear bodies. We also performed immunoprecipitation analyses on cotransfected COS7 cells, which revealed the presence of PIASx β among the proteins precipitated with an antibody directed against Krox20 (Figure 1D). Together, these data demonstrate that Krox20 and PIASx β can interact *in vivo*.

Identification of the PIASx β /Krox20 interaction domains

Several domains have been predicted within PIASx β , on the basis of amino-acid sequence analysis and comparison with protein sequence databases (Figure 2A): an N-terminal SAP domain, containing a putative DNA-binding bi-helical motif (Aravind and Koonin, 2000); a proline-rich, putative SH3-binding domain (Wu *et al*, 1997); a core region containing an SP-RING, related to RING zinc-fingers present in many E3 ubiquitin ligases and known to be required for Ubc9 binding and SUMO ligase activity of PIAS family members (Kahyo *et al*, 2001; Sachdev *et al*, 2001); a SIM domain for non-covalent SUMO binding (Minty *et al*, 2000); a nuclear localization signal (NLS); a C-terminal serine/threonine-rich domain, which has been shown to be required for transcription activation in Gal4 fusions in yeast (Wu *et al*, 1997).

To determine which region(s) of PIASx β are important for physical interaction with Krox20, we first generated a series of external deletions. The interactions with Krox20 were then analysed by GST pull-down as described above (Figure 2A). Quantitative analysis of the retention of deleted proteins as compared to full-length PIASx β indicated that amino acids upstream to position 132 or downstream to position 286 were not essential for efficient interaction with Krox20 (Figure 2A and B). Consistently, a region corresponding to amino-acid sequence 101–286 and encompassing the proline-rich region was sufficient for binding (Figure 2A and B). To confirm these data and localize the region of interaction more precisely, we analysed internal PIASx β deletion mutants in the yeast two-hybrid system, using the Gal4 site-driven β -galactosidase reporter. Consistent with the external deletion analysis, deletion of amino acids 102–162 (Δ Pro) completely abolished the interaction with Krox20 (Figure 2C). The interface domain

was more precisely localized to the 133–162 region, which contains the proline-rich domain, as its deletion severely impaired the interaction, whereas deletion of region 102–131 did not affect binding (Figure 2C). In agreement with these data, another PIAS family member, PIAS γ , which shows a general high sequence similarity to PIASx β but totally differs from it at the level of the proline-rich domain, did not interact with Krox20 (Figure 2C).

The region of the Krox20 protein required for the interaction with PIASx β was subsequently localized in a similar manner, using a series of external deletions and monitoring β -galactosidase reporter activity in the yeast two-hybrid system. We found that the zinc-finger region, corresponding to the DNA-binding domain, was necessary and sufficient for effective interaction with PIASx β (Figure 2D). Attempts to further delimit the region of interaction were unsuccessful, as elimination of the first or the third zinc-finger led to loss of Krox20/PIASx β interaction (data not shown). This suggests that the domain of interaction with PIASx β overlaps with the entire Krox20 DNA-binding domain.

PIASx β can antagonize Krox20 transcriptional activity

The physical interaction observed between Krox20 and PIASx β , both *in vitro* and *in vivo*, raised the possibility of a functional interaction between the two proteins in the developing hindbrain. To investigate this possibility, we turned to the chick embryo in which gain-of-function experiments can easily be performed by *in ovo* electroporation. We first analysed the expression of PIASx β by *in situ* hybridization to determine whether *Krox20* and *PIASx β* are coexpressed during hindbrain segmentation. We found that *PIASx β* expression is induced in the anterior part of the neural tube around the 3–4 somite stage (ss) and that this expression rapidly extends caudally to form an AP-decreasing gradient at the 5–6 ss (Figure 3A and data not shown). *Krox20* is expressed in r3 from 4 to 5 ss and in r5 from 7 to 8 ss (Irving *et al*, 1996; Giudicelli *et al*, 2001) and therefore the two genes are coexpressed in these rhombomeres. Around the 12–16 ss, *PIASx β* is downregulated posterior to r2, except at the level of r4 (Figure 3B). Around the 24–30 ss stage, *PIASx β* expression appeared generally decreased in the neural tube (data not shown).

We then investigated the consequences of *PIASx β* ectopic expression in the developing hindbrain. The HA-tagged *PIASx β* expression plasmid was unilaterally electroporated in the chick neural tube at the 4–8 ss. Electroporated embryos were recovered at 20 ss and we analysed the patterns of expression of different segmentally expressed genes by *in situ* hybridization, first focusing on genes that are directly, positively regulated by Krox20: *Krox20* itself and *EphA4* (Theil *et al*, 1998; Giudicelli *et al*, 2001). *Krox20* and *EphA4* expressions, which are restricted to r3 and r5, were severely affected on the electroporated side, with the appearance of large patches of non-expressing cells in these rhombomeres (Figure 3C and D), indicating that *PIASx β* can repress these genes. Double immunolabelling experiments, designed to detect both the *EphA4* protein and the electroporated, tagged *PIASx β* , revealed that the loss of *EphA4* in a cell is correlated with the presence of exogenous *PIASx β* (Figure 3E), indicating that the repression occurs in a cell-autonomous manner. The formation of *Krox20*- or *EphA4*-negative patches could therefore be due to a phenomenon of segregation, as




Figure 2 Identification of the domains involved in PIASxβ/Krox20 interaction. (A) Schematic representation of the PIASxβ structural domains and of the deletion mutants. PIASxβ contains SAP, proline-rich (Pro), SP-RING, SIM domains, an NLS and a C-terminal serine/threonine-rich (Ser/Thr) domain. Numbers below the line indicate amino-acid positions. The amino-acid positions of the extremities of truncated PIASxβ proteins are indicated on the left. The efficiency of the binding to Krox20, indicated in percentage on the right, was estimated from the recovery of each deleted protein after GST-Krox20 pull-down assay (see part B), normalized with wild-type PIASxβ. The PIASxβ interacting region was localized between amino acids 132 and 286. (B) GST-Krox20 pull-down assay performed on deleted PIASxβ. *In vitro*-translated, ³⁵S-labelled PIASxβ truncated proteins were resolved by SDS-PAGE and detected by fluorography. Left: deposit of 20% of the input proteins; right: PIASxβ proteins recovered after binding to immobilized GST-Krox20 protein. (C) Quantitative yeast two-hybrid assay performed on PIASxβ deletions. PIASγ and a series of PIASxβ deletions fused to the GAL4 activation domain were evaluated for their capacity to bind to a Krox20-Gal4 DNA-binding domain bait by measuring the expression of a *lacZ* reporter. The β-galactosidase activity was normalized by the level obtained with the wild-type PIASxβ construct. The PIASxβ proline-rich domain appears necessary for the interaction with Krox20. Control corresponds to no PIASxβ insert. (D) Identification of the Krox20 domain required for the interaction with PIASxβ, using the quantitative yeast two-hybrid assay. In this case, a series of Krox20 deletions fused to the Gal4 DNA-binding domain were confronted to the wild-type PIASxβ-Gal4 activation domain fusion and the interaction was recorded by measuring the expression of the *lacZ* reporter gene. The β-galactosidase activity was normalized by the level obtained with the 184-470 Krox20 deletion construct. The region of interaction with PIASxβ was localized within the zinc-finger domain. Control corresponds to no Krox20 insert.

previously reported (Giudicelli *et al*, 2001). No repression of *Epha4* expression was observed when the hindbrain was electroporated with the ΔPro mutant, which has lost the ability to interact with Krox20 (Figure 3F). This suggests that the repression activity of PIASxβ involves antagonizing Krox20-positive transcriptional activity. This latter possibility was reinforced by the observation that *Hoxa2*, another positive target of Krox20, was also repressed by PIASxβ (data not shown). In contrast, the expression patterns of two genes whose regulation is known to be independent of Krox20,

Hoxa3 and *MafB* (Giudicelli *et al*, 2001; Manzanares *et al*, 2002), were not affected by ectopic PIASxβ expression (Figure 3G and H). Finally, taken together, our data indicate that PIASxβ appears capable of preventing the transcriptional activation of all the genes tested that are positively regulated by Krox20, presumably by directly antagonizing Krox20.

PIASxβ act as an activator of *Hoxb1* expression

We next investigated whether PIASxβ could also interfere with the expression of genes that are downregulated by




Figure 3 Ectopic *PIASxβ* expression antagonizes *Krox20* activity and leads to *Hoxb1* activation. (A, B) Analysis of *PIASxβ* expression in chick embryos. Whole-mount *in situ* hybridization on 6 ss (A) or 14 ss (B) embryos. At 6 ss, *PIASxβ* is expressed in the neural tube in a decreasing AP gradient. At 14 ss, higher levels of expression are maintained in the anterior CNS up to r2 and in r4. (C–M) Flat-mounted hindbrains from chick embryos electroporated between stages 3 and 8 ss with expression plasmids for the proteins indicated above. The embryos were collected 24 h after electroporation and expression of the markers indicated below was analysed by *in situ* hybridization (C, D, F–M) or immunohistochemistry (E). (C, D) *Krox20* and *EphA4* are repressed in r3 and r5. (E) Double immunohistochemistry with anti-*EphA4* (green) and anti-HA (red) antibodies. *EphA4*-negative patches in r3 and r5 are positive for HA-*PIASxβ*. Only the left (electroporated) side of the embryo is shown. (F) Δ Pro, which has lost the ability to interact with *Krox20*, does not repress *EphA4*. (G–I) *Hoxa3*, *MafB* and *follistatin* are not affected by *PIASxβ*. (J–M) *Hoxb1* is ectopically activated by *PIASxβ* and this activity is antagonized by co-electroporated *Krox20* (M). In r3 and r5, *Hoxb1* expression domains coincide with the *EphA4*-negative patches (L). Electroporations were always performed on the left side.

Krox20. The *follistatin* gene is expressed in r2 and r4–r6 around the 20 ss in the chick (Figure 3I), and is known to be repressed by *Krox20* in r3 (Seitanidou *et al*, 1997). Its expression was not modified by *PIASxβ* electroporation (Figure 3I), suggesting that *PIASxβ* is not able to interfere with *Krox20* repressive activity in this case.

Another gene subjected to repression by *Krox20* is *Hoxb1*, a major determinant of r4 identity: in particular, we have previously demonstrated that ectopic *Krox20* expression leads to *Hoxb1* repression in r4, r6 and the spinal cord (Giudicelli *et al*, 2001) and that *Krox20* loss-of-function mutation allows

rostral extension of *Hoxb1* expression in r3 (Voiculescu *et al*, 2001). Ectopic *PIASxβ* expression resulted in *Hoxb1* activation outside of its territories of normal expression, an increase in its level of expression in r6 and the spinal cord and an enlargement of the r4 domain (Figure 3J and L). In r3 and r5, the domains of activation of *Hoxb1* precisely corresponded to the patches of repression of *EphA4* (Figure 3L and data not shown). Surprisingly, this ectopic activation of *Hoxb1* expression was observed at least from the midbrain to the spinal cord and was therefore not restricted to the territories of *Krox20* expression. This indicates that the capacity of *PIASxβ*

to activate *Hoxb1* is not dependent on Krox20. Nevertheless, co-electroporation of *Krox20* and *PIASxβ* expression vectors indicated that the two proteins can antagonize each other: *PIASxβ* could prevent activation of *EphA4* by Krox20 (compare Figure 3K and M) and reciprocally Krox20 could prevent activation of *Hoxb1* by *PIASxβ* (compare Figure 3L and M).

In conclusion, we unexpectedly found that *PIASxβ* acts as an activator of *Hoxb1* expression, independently of Krox20. As *Hoxb1* is under Krox20 negative control and Krox20 can antagonize *PIASxβ*-inducing activity, this raises the possibility that Krox20 may actually repress *Hoxb1* by antagonizing *PIASxβ* *in vivo*.

PIASxβ is involved in *Hoxb1* activation

To further investigate the involvement of *PIASxβ* in the control of *Hoxb1* expression, we generated a series of HA-tagged, external and internal deletion mutants that were tested by electroporation in the chick hindbrain (Figure 4A). In order to normalize our analysis, the relative amount of protein produced by these different constructs was estimated

by anti-HA immunohistochemistry on electroporated embryos. No major variations were observed (data not shown).

Deletion of the N-terminal SAP domain abrogated *Hoxb1* activation but preserved *EphA4* repression (Figure 4B–D). In contrast, the SP-RING domain was surprisingly not required for either activity (Figure 4F and G). Deletion of the proline-rich domain prevented *Hoxb1* activation (Figure 4E). Finally, the deletion of the C-terminal serine/threonine-rich region turned out to be particularly interesting. This mutant had not only lost the capacity to activate *Hoxb1*, but it actually appeared to repress endogenous *Hoxb1* expression (Figure 4H) and to antagonize wild-type *PIASxβ* in this respect (Figure 4I). The Δ SerThr mutant kept its capacity to repress *EphA4* (Figure 4J), consistent with the maintenance of the interaction with Krox20. It did not interfere with the expression of *MafB* (data not shown), a gene that we have shown previously not to be affected by the ectopic expression of wild-type *PIASxβ* (Figure 3H). This latter observation indicates that the acquisition of an *Hoxb1* repression capacity by the Δ SerThr mutant is specific and does not reflect a general repressive activity of the construct.




Figure 4 Identification of *PIASxβ* domains required for *Hoxb1* activation. (A) Schematic representation of *PIASxβ* and deletion mutants (see Figure 2 for details). (B–J) Flat-mounted hindbrains from chick embryos electroporated on the left side with the constructs indicated above and *in situ* hybridized with the probes indicated below. Whereas deletion of the SP-RING domain does not affect the activity of *PIASxβ* (B, F, G), elimination of the SAP domain prevents activation of *Hoxb1* without affecting the repression of *EphA4* (C, D), and deletion of the proline-rich domain prevents activation of *Hoxb1* (E). Deletion of the serine/threonine-rich domain does not affect *EphA4* repression (J), but transforms *PIASxβ* into a repressor of *Hoxb1* (H), able to antagonize the wild-type protein (I).

In conclusion, these data indicate that the SAP and proline-rich domains are required for *Hoxb1* transcriptional activation, whereas the SP-RING domain is not. The specific repression of *Hoxb1* by the Δ SerThr mutant suggests that this mutant acts as a dominant-negative molecule and competes with endogenous PIASx β , supporting the notion that PIASx β is involved in the normal transcriptional activation of *Hoxb1*.

Krox20 does not require DNA binding to repress *Hoxb1*

The data presented above suggest that the repression of *Hoxb1* by Krox20 is mediated by the interaction of Krox20 with PIASx β , an activator of *Hoxb1*. However, we have previously shown that, when a point mutation preventing DNA binding was introduced into the third zinc-finger of Krox20, corresponding to an arginine to tryptophan substitution (R409W) observed in a human peripheral myelinopathy (Warner *et al*, 1998, 1999), *Hoxb1* repression by Krox20 was abolished (Giudicelli *et al*, 2001; Figure 5B). The latter experiment rather suggested that Krox20 repression of *Hoxb1* required DNA binding by Krox20. Therefore, we have further examined the involvement of DNA binding in Krox20 repression of *Hoxb1*. For this purpose, we have compared the activities of the wild-type Krox20 protein on *Hoxb1* and *EphA4* expression with R409W and another human peripheral myelinopathy mutant, S382R/D383Y, which corresponds to serine and aspartic acid to arginine and tyrosine substitutions in the second zinc-finger (Warner *et al*, 1998) and is also defective in DNA binding (Warner *et al*, 1999).

As indicated above, R409W has lost the ability to repress *Hoxb1* (Figure 5A and B). It is also unable to induce ectopic *EphA4* expression (Figure 5E and F), consistent with the fact that *EphA4* has been shown to constitute a direct transcriptional target of Krox20 (Theil *et al*, 1998). S382R/D383Y presented a strikingly different behaviour: whereas it was unable to activate *EphA4* (Figure 5G), it repressed *Hoxb1* (Figure 5C). Furthermore, a deleted Krox20 protein containing only the 160 C-terminal amino acids, including the zinc-fingers, and carrying the double mutation S382R/D383Y (CterSR/DY) was also able to repress *Hoxb1* and unable to activate *EphA4* (Figure 5D and H). Finally, these data were confirmed using co-electroporation of constructs carrying a *lacZ* reporter under the control of a β -globin minimal promoter and *EphA4* and *Hoxb1* *cis*-acting regulatory sequences (see Supplementary data). The effects on the reporter constructs were fully consistent with those observed on the endogenous *EphA4* and *Hoxb1* genes (Supplementary Figure 1).

In conclusion, this analysis clearly establishes that the DNA-binding activity of Krox20, although absolutely required for *EphA4* induction, is not necessary to repress *Hoxb1*. This latter conclusion is in sharp contrast with what could have been deduced from the sole examination of the R409W mutant.

***Hoxb1* repression by Krox20 correlates with binding to PIASx β**

As the two examined point mutants in Krox20 zinc-fingers differed drastically in their capacity to repress *Hoxb1*, we




Figure 5 *Hoxb1* repression by Krox20 does not require DNA binding. (A–H) Flat-mounted hindbrains from chick embryos electroporated on the left side with wild-type and mutant Krox20 constructs as indicated above and *in situ* hybridized with *Hoxb1* or *EphA4* probes. (A–D) Whereas the R409W mutation prevents repression of *Hoxb1*, S382R/D383Y and CterSR/DY conserve this activity, despite their loss of DNA binding. (E–H) In the three mutants, loss of DNA binding correlates with the inability to activate *EphA4*.

investigated whether this behaviour could be correlated with their ability to interact with PIASxβ. This latter property was estimated in the yeast two-hybrid system using the *lacZ* reporter driven by the PIASxβ-Gal4 hybrid as indicated above. We found that the R409W mutant was highly impaired in its activation of the reporter, whereas the behaviour of the S382R/D383Y mutant was close to that of the wild-type protein (Figure 6). As controls, we performed the same assay, but using a Par4-Gal4 hybrid as *lacZ* driver. Par4 is another interactor of the zinc-finger domain of Krox20 identified in the two-hybrid screening (data not shown). The two Krox20 mutants appeared to perform very similarly and slightly better than the wild type in this latter assay, indicating that the differences observed with the PIASxβ-Gal4 driver are not due to differences in the synthesis or stability of the two mutant proteins, but rather in the capacity to interact with PIASxβ (Figure 6).

In conclusion, these results establish that the R409W is strongly hampered in its interaction with PIASxβ, whereas S382R/D383Y behaves similarly to the wild-type protein. This indicates that although DNA-binding and PIASxβ interaction domains overlap within the Krox20 protein, they are distinct and at least DNA binding can be abolished without seriously affecting PIASxβ binding. In addition, we observed that in these two mutants, the capacity of Krox20 to repress *Hoxb1* correlates with its ability to interact with PIASxβ, supporting the idea that Krox20 represses *Hoxb1* by antagonizing one of its activators, PIASxβ. This conclusion was further supported by the observation that co-electroporation with PIASxβ can release Krox20-mediated repression of *Hoxb1*, whereas this is not the case with ΔPro, which cannot interact with Krox20 (data not shown).

Discussion

In this study, we have identified PIASxβ as a novel interactor of Krox20, which plays an important role in hindbrain segmentation, regulating the expression of several *Hox* genes. We unexpectedly found that PIASxβ is able to activate *Hoxb1* expression and that its interaction with Krox20 is likely to constitute the molecular basis of *Hoxb1* repression by Krox20 in the hindbrain. Our findings reveal an additional level of complexity in the mechanisms controlling *Hox* gene regulation and raise the possibility that PIAS family members might be involved in novel and important developmental regulatory processes.

Direct interaction between Krox20 and PIASxβ

We have accumulated several lines of evidence supporting a direct biochemical and functional interaction between Krox20 and PIASxβ: (i) the existence of the interaction was initially established in a yeast two-hybrid assay, which also allowed, together with GST pull-down experiments, to define the interaction interfaces on each proteins; (ii) GST pull-down data also established that binding was direct (Figure 1B); (iii) the existence of an *in vivo* interaction was supported by the coexpression of the two genes in the developing hind-brain, by the subcellular relocalization of Krox20 upon forced expression of PIASxβ in mammalian cells (Figure 1C) and by co-immunoprecipitation of the two proteins (Figure 1D). Colocalization of Krox20 with the different PIASxβ deletion mutants (Supplementary Figure 2) adds support to this conclusion; (iv) the functionality of the interaction is supported by the crossregulatory activities of the two proteins.

The discovery of this novel interaction raises a number of interesting points. It first adds to the list of Krox20 interactors, illustrating the importance and the complexity of the regulatory activities of Krox20. As PIASxβ carries an E3 ligase activity, SUMOylation of Krox20 by PIASxβ might have been envisaged. However, several pieces of data are against this possibility: (i) Krox20 does not contain any SUMOylation consensus site; (ii) preliminary *in vitro* SUMOylation assays failed to reveal any SUMOylated form of Krox20 (data not shown); (iii) the deletion of the ΔRING domain is known to inactivate the E3 ligase activity and nevertheless it does not prevent PIASxβ from antagonizing Krox20 (Figure 4). The precise localization of the interaction interfaces between Krox20 and PIASxβ revealed a large overlap with the DNA-binding domain in Krox20, as both zinc-fingers 1 and 3 appear to be required. However, overlap does not mean identity, as we have found a mutation that abolishes DNA binding without significantly affecting PIASxβ binding (Figure 6). Such an overlap has implications at both structural and functional (binding to each target is likely to be exclusive) levels. In PIASxβ, the interaction domain has been shown to include a proline-rich region whose structure has not yet been established but resembles the SH3 domain-binding region of the GAP protein 3BP-1 (Wu *et al*, 1997).

Both Krox20 and PIASxβ belong to highly conserved multi-gene families. The interaction between Krox20 and PIASxβ raises the possibility of the existence of similar interactions between other members of the families. The zinc-fingers are extremely conserved between Krox20 and the three other members of the Krox20/Egr family (see O'Donovan *et al*,




Figure 6 The ability of Krox20 to repress *Hoxb1* correlates with its capacity to interact with PIASxβ. The 184–470 Krox20 deletions, in their wild-type version or carrying mutations in the DNA-binding domain, fused to the Gal4 DNA-binding domain were confronted to the Gal4 activation domain fused to PIASxβ or Par4 in the yeast two-hybrid system. The interaction was recorded by measuring the expression of the *lacZ* reporter gene. The β-galactosidase activities were normalized with the levels obtained with the wild-type construct. Mutant S382R/D383Y, which has retained *Hoxb1* repression activity, has also maintained its capacity to interact with PIASxβ, whereas R409W has lost both activities. As a control, interaction with Par4 is not seriously affected in either mutant. Control corresponds to no Krox20 insert.

1999 for a review), suggesting that these proteins are likely to bind PIAS as well. PIASx β and PIASx α are splice variants that are identical in the binding domain. PIASx α should therefore also bind to Krox20. We showed that the sequence between positions 133 and 162 in PIASx β is absolutely required for binding. This sequence is not present in PIAS γ and accordingly this protein does not bind to Krox20 (Figure 2C). This sequence is also poorly conserved between PIASx β and PIAS1 and PIAS3, with the exception of the hexapeptide Pro-Val-His-Pro-Asp-Val/Ile. Consistently, binding of Krox20 to PIAS3 is poor and interaction with PIAS1 is significant, but much lower than with PIASx β (Supplementary Figure 3). Accordingly, we did not observe a repression of Krox20 targets upon electroporation of PIAS1 or PIAS3 expression vectors in chick embryos (data not shown).

Hoxb1 regulation by PIASx β

The patterns of expression of *Hoxb1* and PIASx β in the developing nervous system only partially overlap and in particular *Hoxb1* is expressed caudally up to the prospective r3/r4 boundary at the 2–3 ss stage in the chick, before PIASx β induction (Giudicelli *et al*, 2001 and this paper), excluding the possibility of a role of PIASx β in *Hoxb1* early activation. At later stages, however, PIASx β is likely to be implicated in the positive regulation of *Hoxb1* in the hindbrain and the spinal cord. This is based both on gain-of-function experiments in which we ectopically expressed PIASx β in the chick embryo neural tube and on loss-of-function experiments involving expression of a PIASx β mutant derivative that presumably acts as a dominant-negative molecule.

Our experiments did not address at which level PIASx β is acting on *Hoxb1* expression. Transcription initiation nevertheless constitutes the most likely possibility. This is consistent with several observations: (i) PIASx β is able to induce accumulation of *Hoxb1* mRNA in territories that normally do not express the gene. (ii) Although PIAS family members have been mostly described as transcriptional corepressors (Schmidt and Muller, 2003), roles of transcriptional coactivators have also been reported (Yang and Sharrocks, 2005). Hence, PIASx β interacts with a histone deacetylase (HDAC) to alleviate transcriptional repression on TFII-I (Tussié-Luna *et al*, 2002). It is interesting to note that the SAP domain, which is required for *Hoxb1* activation, has been shown to be involved in the interaction with HDACs (Gross *et al*, 2004). (iii) The C-terminus of PIASx β , which is also required for *Hoxb1* activation, is rich in serine and threonine like some transcriptional activation domains and has been shown to activate transcription in Gal4 fusions in yeast (Wu *et al*, 1997).

Definitive proof for the requirement of PIASx β in some aspects of *Hoxb1* transcription will await the analysis of the knockout mutants. However, owing to the close conservation of the different family members, this is likely to necessitate the combination of mutations in several of them.

Krox20, a molecular switch for coordinated *Hox* gene regulation

Hoxb1 transcriptional regulation in the developing central nervous system (CNS) is a very complex process. It has been shown to involve an initiation period involving induction by *Hoxa1* and the retinoic acid pathway followed by a maintenance and refinement period. This second phase involves

both positive regulators, in particular, Pbx, Meis and Hox factors acting through auto- and crossregulatory pathways, and repressors that lead to restriction of the expression to r4. Krox20 belongs to these negative regulators, as indicated by its capacity to repress *Hoxb1* expression in gain-of-function experiments in the chick and by the extension of the *Hoxb1*-positive territory into r3 in the mouse *Krox20* null mutant (Giudicelli *et al*, 2001; Voiculescu *et al*, 2001). The present work provides a molecular basis for the genetic interaction between Krox20 and *Hoxb1*. We propose that PIASx β is required for the second phase of *Hoxb1* expression in the hindbrain and that Krox20 represses *Hoxb1* by directly binding to PIASx β and antagonizing its activity (Figure 7). In contrast, the early pattern of expression of PIASx β in the CNS, with no rhombomere-specific domains (Figure 3A), is not in favour of an implication of PIASx β in the control of Krox20 activity. The mechanism of repression by Krox20 is very different from its mode of activation of gene expression, which involves specific DNA binding, although the same domain, the zinc-fingers, is involved in both types of interactions (Figure 7). Our interpretation is strongly supported by the fact that *Hoxb1* repression does not require the ability of Krox20 to bind DNA, and that it correlates with the capacity of Krox20 to interact with PIASx β . According to our model, odd- (r3/r5) or even- (r4) numbered rhombomere-specific expression relies on the balance between Krox20 and PIASx β : when in excess, Krox20 both antagonizes PIASx β , leading to *Hoxb1* repression, and binds to its DNA target sites, directly activating the transcription of odd-numbered rhombomere-specific genes, including *Hox* genes (Figure 7A). In contrast, in the absence of Krox20, PIASx β is free to activate *Hoxb1* expression and odd-numbered genes are not activated (Figure 7B). Therefore, Krox20 appears as a molecular switch




Figure 7 Schematic representation of the possible crossregulatory interactions between Krox20 and PIASx β . The relative levels of the two proteins determine the expression of r3/r5- and r4-specific genes (see the Discussion section for details of the model). The circles represent the different proteins and the rectangle the cis-acting elements. (A) Situation in r3/r5. (B) Situation in r4. The interaction of PIASx β with the *Hoxb1* locus may be direct or indirect, via a putative protein (X). The domain of PIASx β involved in this latter interaction has not been characterized. It is arbitrarily represented as the domain overlapping with the Krox20-binding domain. This representation does not take into account the possibility that PIASx β might be acting by sequestering a repressor of *Hoxb1*.

that coordinates gene expression to establish odd-numbered rhombomere identity.

The precise mode of action of Krox20 on PIASx β activity is not known. However, we have shown that on PIASx β the interaction occurs at the level of a region that contains an SH3-binding domain (proline-rich region). Therefore, binding of Krox20 to the proline-rich region may prevent the interaction of PIASx β with an SH3 factor and its incorporation into a transcription activation complex. In support of this idea, the deletion of the proline-rich domain not only prevents interaction with Krox20, but also abrogates *Hoxb1* activation. Identification of this putative SH3 factor will constitute a further step in the understanding of *Hoxb1* regulation.

Materials and methods

Yeast two-hybrid screening and yeast β -galactosidase assays

For all constructions, see Supplementary data. Yeast two-hybrid screening was performed with the ProQuest Two-Hybrid System (Invitrogen) in the MaV203 strain, according to the manufacturer's protocol. We used a ProQuest two-hybrid, 8.5 dpc mouse embryo cDNA library cloned in the pPC86 vector (Invitrogen). Quantification of β -galactosidase activity was performed using *o*-nitrophenyl- β -D-galactopyranoside as substrate.

Protein expression, purification, immunoprecipitation and pull-down assays

GST and GST fusion constructs were transformed in *Escherichia coli* BL21(DE3) and GST fusions were prepared and purified on glutathione-Sepharose beads (Amersham Biosciences Inc.) according to the manufacturer's protocol. *In vitro* transcription/translation reactions were performed with the TNT Quick Coupled Transcription/Translation System (Promega) in the presence of [³⁵S]methionine (Amersham Biosciences Inc.) using 1 μ g of template plasmid. Pull-down experiments and protein immunoprecipitation are detailed in Supplementary data.

References

- Aravind L, Koonin EV (2000) SAP—a putative DNA-binding motif involved in chromosomal organization. *Trends Biochem Sci* **25**: 112–114
- Barrow JR, Stadler HS, Capecchi MR (2000) Roles of *Hoxa1* and *Hoxa2* in patterning the early hindbrain of the mouse. *Development* **127**: 933–944
- Birgbauer E, Sechrist J, Bronner-Fraser M, Fraser S (1995) Rhombomeric origin and rostrocaudal reassortment of neural crest cells revealed by intravital microscopy. *Development* **121**: 935–945
- Cheng YC, Amoyel M, Qiu X, Jiang YJ, Xu Q, Wilkinson DG (2004) Notch activation regulates the segregation and differentiation of rhombomere boundary cells in the zebrafish hindbrain. *Dev Cell* **6**: 539–550
- Choe SK, Sagerstrom CG (2004) Paralog group 1 hox genes regulate rhombomere 5/6 expression of *vhnf1*, a repressor of rostral hindbrain fates, in a meis-dependent manner. *Dev Biol* **271**: 350–361
- Clarke JD, Erskine L, Lumsden A (1998) Differential progenitor dispersal and the spatial origin of early neurons can explain the predominance of single-phenotype clones in the chick hindbrain. *Dev Dyn* **212**: 14–26
- Dupe V, Lumsden A (2001) Hindbrain patterning involves graded responses to retinoic acid signalling. *Development* **128**: 2199–2208
- Fraser S, Keynes R, Lumsden A (1990) Segmentation in the chick embryo hindbrain is defined by cell lineage restrictions. *Nature* **344**: 431–435
- Frohman MA, Martin GR, Cordes SP, Halamek LP, Barsh GS (1993) Altered rhombomere-specific gene expression and hyoid bone differentiation in the mouse segmentation mutant, *kreisler* (*kr*). *Development* **117**: 925–936
- Gavalas A, Studer M, Lumsden A, Rijli FM, Krumlauf R, Chambon P (1998) *Hoxa1* and *Hoxb1* synergize in patterning the hindbrain, cranial nerves and second pharyngeal arch. *Development* **125**: 1123–1136
- Giudicelli F, Taillebourg E, Charnay P, Gilardi-Hebenstreit P (2001) Krox-20 patterns the hindbrain through both cell-autonomous and non cell-autonomous mechanisms. *Genes Dev* **15**: 567–580
- Graham A, Lumsden A (1996) Interactions between rhombomeres modulate Krox-20 and *follistatin* expression in the chick embryo hindbrain. *Development* **122**: 473–480
- Grapin-Botton A, Bonnain MA, McNaughton LA, Krumlauf R, Le Douarin NM (1995) Plasticity of transposed rhombomeres: Hox gene induction is correlated with phenotypic modifications. *Development* **121**: 2707–2721
- Gross M, Yang R, Top I, Gasper C, Shuai K (2004) PIASy-mediated repression of the androgen-receptor is independent of sumoylation. *Oncogene* **23**: 3059–3066
- Guthrie S, Muchamore I, Kuroiwa A, Marshall H, Krumlauf R, Lumsden A (1992) Neuroectodermal autonomy of Hox-2.9 expression revealed by rhombomere transpositions. *Nature* **356**: 157–159
- Hirano S, Tanaka H, Ohta K, Norita M, Hoshino K, Meguro R, Kase M (1998) Normal ontogenic observations on the expression of Eph receptor tyrosine kinase, *Cek8*, in chick embryos. *Anat Embryol (Berl)* **197**: 187–197
- Irving C, Nieto A, DasGupta R, Charnay P, Wilkinson DG (1996) Progressive spatial restriction of *Sek-1* and *Krox-20* gene expression during hindbrain segmentation. *Dev Biol* **173**: 26–38

Cell culture, transfections and indirect immunofluorescence

COS7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum (Invitrogen). Transient transfections were performed with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Cells were analysed 36 h after transfection. For immunofluorescence analysis, cells were permeabilized for 2 min at room temperature with 0.5% Triton X-100 in PBS, fixed for 10 min in 4% paraformaldehyde (PFA) in PBS and blocked with 10% fetal bovine serum in PBS containing 0.1% Triton X-100. Dissected hindbrains were fixed for 2 h in 4% PFA in PBS and blocked with 5% donkey serum in PBS containing 0.25% Triton X-100. Antibodies and dilutions were as follows: Krox20, rabbit polyclonal (1:100; Babco); HA, rat monoclonal (1:400; Roche); EphA4, mouse monoclonal (1:50; Hirano *et al*, 1998); FITC- and Cy3-conjugated secondary antibodies (1:200 and 1:800, respectively; Jackson Immuno Research). Immunofluorescence pictures were acquired on a Leica TCS 4D confocal microscope and assembled with Adobe Photoshop.

In ovo electroporation and whole-mount in situ hybridization

Electroporation, preparation of the embryos for immunocytochemistry and *in situ* hybridization were carried out as described previously (Giudicelli *et al*, 2001). To evaluate the efficiency of electroporation, a GFP expression vector (pEGFP-N1; Clontech) was systematically co-electroporated. The chick probes for *in situ* hybridization were as follows: *Krox20* (Giudicelli *et al*, 2001), *EphA4* (Sajjadi and Pasquale, 1993), *MafB* (Kataoka *et al*, 1994), *Hoxa3* (Grapin-Botton *et al*, 1995), *Hoxb1* (Guthrie *et al*, 1992), *follistatin* (Graham and Lumsden, 1996), *PIASx β* (BBSRC chick EST ChEST604b10, ChEST350g13 and ChEST289m24).

Supplementary data

Supplementary data are available at *The EMBO Journal* Online.

Acknowledgements

We thank J Ghislain for critical reading of the manuscript and A Dejean and J Seeler for help in the Somoylation assay. MG-D was supported by Marie Curie (European Union) and Ramon y Cajal (MEC, Spain) contracts. This work was supported by grants from INSERM, MENRT, EC, ARC and AFM to PC.

- Johnson ES (2004) Protein modification by SUMO. *Annu Rev Biochem* **73**: 355–382
- Kahyo T, Nishida T, Yasuda H (2001) Involvement of PIAS1 in the sumoylation of tumor suppressor p53. *Mol Cell* **8**: 713–718
- Kataoka K, Fujiwara KT, Noda M, Nishizawa M (1994) MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. *Mol Cell Biol* **14**: 7581–7591
- Kotaja N, Karvonen U, Janne OA, Palvimo JJ (2002) PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. *Mol Cell Biol* **22**: 5222–5234
- Lumsden A, Krumlauf R (1996) Patterning the vertebrate neuraxis. *Science* **274**: 1109–1115
- Manzanares M, Nardelli J, Gilardi-Hebenstreit P, Marshall H, Giudicelli F, Martinez-Pastor MT, Krumlauf R, Charnay P (2002) Krox20 and kreisler co-operate in the transcriptional control of *Hoxb3* hindbrain segmental expression. *EMBO J* **21**: 365–376
- Marin F, Charnay P (2000) Hindbrain patterning: FGFs regulate Krox20 and mafB/kr expression in the otic/preotic region. *Development* **127**: 4925–4935
- McNulty CL, Peres JN, Bardine N, van den Akker WM, Durston AJ (2005) Knockdown of the complete Hox paralogous group 1 leads to dramatic hindbrain and neural crest defects. *Development* **132**: 2861–2871
- Minty A, Dumont X, Kaghad M, Caput D (2000) Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. *J Biol Chem* **275**: 36316–36323
- Nonchev S, Vesque C, Maconochie M, Seitanidou T, Ariza-McNaughton L, Frain M, Marshall H, Sham MH, Krumlauf R, Charnay P (1996) Segmental expression of Hoxa-2 in the hindbrain is directly regulated by Krox-20. *Development* **122**: 543–554
- O'Donovan KJ, Tourtellotte WG, Millbrandt J, Baraban JM (1999) The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. *Trends Neurosci* **22**: 167–173
- Pasini A, Wilkinson DG (2002) Stabilizing the regionalisation of the developing vertebrate central nervous system. *BioEssays* **24**: 427–438
- Rijli FM, Mark M, Lakkaraju S, Dierich A, Dolle P, Chambon P (1993) A homeotic transformation is generated in the rostral branchial region of the head by disruption of Hoxa-2, which acts as a selector gene. *Cell* **75**: 1333–1349
- Rossel M, Capocchi MR (1999) Mice mutant for both Hoxa1 and Hoxb1 show extensive remodeling of the hindbrain and defects in craniofacial development. *Development* **126**: 5027–5040
- Russo MW, Sevetson BR, Milbrandt J (1995) Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. *Proc Natl Acad Sci USA* **92**: 6873–6877
- Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. *Genes Dev* **15**: 3088–3103
- Sajjadi FG, Pasquale EB (1993) Five novel avian Eph-related tyrosine kinases are differentially expressed. *Oncogene* **8**: 1807–1813
- Schmidt D, Muller S (2003) PIAS/SUMO: new partners in transcriptional regulation. *Cell Mol Life Sci* **60**: 2561–2574
- Schneider-Maunoury S, Topilko P, Seitanidou T, Levi G, Cohen-Tannoudji M, Pournin S, Babinet C, Charnay P (1993) Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. *Cell* **75**: 1199–1214
- Seitanidou T, Schneider-Maunoury S, Desmarquet C, Wilkinson DG, Charnay P (1997) Krox-20 is a key regulator of rhombomere-specific gene expression in the developing hindbrain. *Mech Dev* **65**: 31–42
- Serpente P, Tumpel S, Ghyselincx NB, Niederreither K, Wiedemann LM, Dolle P, Chambon P, Krumlauf R, Gould AP (2005) Direct crossregulation between retinoic acid receptor {beta} and Hox genes during hindbrain segmentation. *Development* **132**: 503–513
- Sham MH, Vesque C, Nonchev S, Marshall H, Frain M, Gupta RD, Whiting J, Wilkinson D, Charnay P, Krumlauf R (1993) The zinc finger gene Krox20 regulates HoxB2 (Hox2.8) during hindbrain segmentation. *Cell* **72**: 183–196
- Shuai K (2000) Modulation of STAT signaling by STAT-interacting proteins. *Oncogene* **19**: 2638–2644
- Studer M, Lumsden A, Ariza-McNaughton L, Bradley A, Krumlauf R (1996) Altered segmental identity and abnormal migration of motor neurons in mice lacking Hoxb-1. *Nature* **384**: 630–634
- Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J (1996) NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. *Mol Cell Biol* **16**: 3545–3553
- Theil T, Frain M, Gilardi-Hebenstreit P, Flenniken A, Charnay P, Wilkinson DG (1998) Segmental expression of the EphA4 (Sek-1) receptor tyrosine kinase in the hindbrain is under direct transcriptional control of Krox-20. *Development* **125**: 443–452
- Trainer PA, Krumlauf R (2000) Patterning the cranial neural crest: hindbrain segmentation and Hox gene plasticity. *Nat Rev Neurosci* **1**: 116–124
- Tussie-Luna MI, Michel B, Hakre S, Roy AL (2002) The SUMO ubiquitin-protein isopeptide ligase family member Miz1/PLASx/Siz2 is a transcription cofactor for TFII-I. *J Biol Chem* **277**: 43185–43193
- Vesque C, Charnay P (1992) Mapping functional regions of the segment-specific transcription factor Krox-20. *Nucleic Acids Res* **20**: 2485–2492
- Voiculescu O, Taillebourg E, Pujades C, Kress C, Buart S, Charnay P, Schneider-Maunoury S (2001) Hindbrain patterning: Krox20 couples segmentation and specification of regional identity. *Development* **128**: 4967–4978
- Walshe J, Maroon H, McGonnell IM, Dickson C, Mason I (2002) Establishment of hindbrain segmental identity requires signaling by FGF3 and FGF8. *Curr Biol* **12**: 1117–1123
- Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR (1998) Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. *Nat Genet* **18**: 382–384
- Warner LE, Svaren J, Milbrandt J, Lupski JR (1999) Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. *Hum Mol Genet* **8**: 1245–1251
- Wu L, Wu H, Ma L, Sangiorgi F, Wu N, Bell JR, Lyons GE, Maxson R (1997) Miz1, a novel zinc finger transcription factor that interacts with Msx2 and enhances its affinity for DNA. *Mech Dev* **65**: 3–17
- Yang SH, Sharrocks AD (2005) PIASx acts as an Elk-1 coactivator by facilitating derepression. *EMBO J* **24**: 2161–2171